
Chiasma, Inc. Net Debt 2011-2026 | CHMA
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Chiasma, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| -15.5 M | -25.3 M | 16 M | 38.4 M | 21.6 M | -35.6 M | -35.5 M | -12.8 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 38.4 M | -35.6 M | -6.08 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
455 M | $ 9.13 | -0.76 % | $ 591 M | ||
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
-2.77 M | $ 0.91 | 2.42 % | $ 6.69 M | ||
|
Edesa Biotech
EDSA
|
-7.74 M | $ 15.52 | -2.39 % | $ 49.6 M | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
-83 M | $ 22.47 | 1.19 % | $ 3.72 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
Fortress Biotech
FBIO
|
-24.8 M | $ 2.24 | 0.9 % | $ 62.5 M | ||
|
Galectin Therapeutics
GALT
|
-25.6 M | $ 2.26 | 0.22 % | $ 144 M | ||
|
Galapagos NV
GLPG
|
-1.29 B | $ 28.07 | 0.75 % | $ 2.69 B | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
Grifols, S.A.
GRFS
|
5.36 B | $ 8.2 | 3.6 % | $ 6.83 B | ||
|
Harmony Biosciences Holdings
HRMY
|
-608 M | $ 31.01 | -0.13 % | $ 1.78 B | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
ImmuCell Corporation
ICCC
|
3.77 M | $ 8.44 | - | $ 76.2 M | ||
|
InflaRx N.V.
IFRX
|
-32.3 M | $ 1.95 | -1.77 % | $ 152 M | ||
|
Immuron Limited
IMRN
|
-21.9 M | $ 0.83 | 3.44 % | $ 6.55 M | ||
|
Incyte Corporation
INCY
|
-3.06 B | $ 98.87 | -0.23 % | $ 19.3 B | ||
|
InMed Pharmaceuticals
INM
|
-8.52 M | $ 0.71 | 1.28 % | $ 1.74 M | ||
|
INmune Bio
INMB
|
-23.7 M | $ 1.35 | 1.5 % | $ 33.4 M | ||
|
Innoviva
INVA
|
-293 M | $ 23.13 | 0.35 % | $ 1.56 B | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
Brainstorm Cell Therapeutics
BCLI
|
533 K | - | -2.5 % | $ 5.88 M | ||
|
BioNTech SE
BNTX
|
-973 M | $ 104.54 | 2.92 % | $ 27.2 B | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | ||
|
Jaguar Health
JAGX
|
116 K | $ 7.55 | -4.13 % | $ 17.6 M | ||
|
KalVista Pharmaceuticals
KALV
|
-55.5 M | $ 26.67 | -0.02 % | $ 1.44 B | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
Innate Pharma S.A.
IPHA
|
-120 M | $ 1.43 | -4.03 % | $ 235 M | ||
|
Kamada Ltd.
KMDA
|
-70.2 M | $ 8.15 | 0.49 % | $ 260 M | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
-25 M | - | - | $ 28.6 M | ||
|
Kazia Therapeutics Limited
KZIA
|
-5.43 M | $ 13.24 | 6.56 % | $ 1.75 B | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
-71 M | $ 223.98 | -0.39 % | $ 4.1 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 3.22 | 7.69 % | $ 5.3 M | ||
|
Liquidia Corporation
LQDA
|
-72.5 M | $ 38.39 | 0.62 % | $ 3.3 B | ||
|
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
Applied Therapeutics
APLT
|
-49.4 M | - | - | $ 8.42 M | ||
|
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | ||
|
Aquestive Therapeutics
AQST
|
-75.5 M | $ 4.08 | 0.74 % | $ 436 M |